Alzheon at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Alzheon takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on valiltramiprosate, its oral anti-amyloid drug, in people with two copies of APOE4. Its work covers effects on plasma p-tau217 and inflammatory markers and the rate of spontaneous ARIA.

Organization	CTAD 2026 Attendance
Alzheon Framingham, Massachusetts
alzheon.com Biotech Develops valiltramiprosate (ALZ-801), an oral anti-amyloid drug tested in APOE4/4 carriers with early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/Aβ42 Ratio in APOE4/4 Homozygotes and their Correlations to Clincial and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD (P011) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial (P012) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Effects of Valiltramiprosate on Plasma P-tau217 and Select Pro-Inflammatory and Vascular Injury Biomarkers with the NULISA CNS Panel: Exploratory Analyses from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD (P013) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Organization

CTAD 2026 Attendance

Alzheon

Framingham, Massachusetts

alzheon.com

Biotech

Develops valiltramiprosate (ALZ-801), an oral anti-amyloid drug tested in APOE4/4 carriers with early Alzheimer's disease.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/Aβ42 Ratio in APOE4/4 Homozygotes and their Correlations to Clincial and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD (P011)

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial (P012)

Anti-amyloid and anti-tau therapies

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Effects of Valiltramiprosate on Plasma P-tau217 and Select Pro-Inflammatory and Vascular Injury Biomarkers with the NULISA CNS Panel: Exploratory Analyses from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD (P013)

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Instantly find 20 buyers from Alzheon

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction